Postexposure prophylaxis with nirmatrelvir-ritonavir for five or 10 days does not reduce the risk for symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to a ...

A Prescription Drug User Fee Act target date of June 16, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...

Doxycycline PEP reduces chlamydia risk but is associated with higher gonorrhea odds in a real-world study of a diverse clinic population.

Persons initiating nPEP should be informed that preexposure prophylaxis (PrEP) can reduce their risk for acquiring HIV in the case of repeat or continuing exposure after the nPEP course. HealthDay ...

Ensitrelavir significantly reduced the likelihood of developing symptomatic COVID-19 following household exposure compared with placebo. Treatment with ensitrelvir was found to prevent symptomatic ...

Doxycycline postexposure prophylaxis (doxyPEP) has the potential to substantially reduce real-world population-level incidence of sexually transmitted infections (STIs), a study in JAMA Internal ...

Post-exposure prophylaxis-in-pocket (PIP) was associated with healthcare savings and improved quality of life outcomes compared to pre-exposure prophylaxis (PrEP), based on data presented at ...

No significant reduction seen in risk for symptomatic SARS-CoV-2 infection with postexposure prophylaxis for 5 or 10 days. (HealthDay News) — Postexposure prophylaxis with nirmatrelvir-ritonavir for 5 ...

Mary R. Tanner, M.D., from the CDC in Atlanta, and colleagues updated the 2016 nPEP guidelines and considerations for use in the United States, including considerations for testing and nPEP regimens ...